دورية أكاديمية
Minding the margins: Evaluating the impact of COVID-19 among Latinx and Black communities with optimal qualitative serological assessment tools.
العنوان: | Minding the margins: Evaluating the impact of COVID-19 among Latinx and Black communities with optimal qualitative serological assessment tools. |
---|---|
المؤلفون: | Binder RA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Matta AM; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Forconi CS; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Oduor CI; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI, United States of America., Bedekar P; Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, United States of America.; Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, United States of America., Patrone PN; Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, United States of America., Kearsley AJ; Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, United States of America., Odwar B; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Batista J; Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Forrester SN; Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Leftwich HK; Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Cavacini LA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America., Moormann AM; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America. |
المصدر: | PloS one [PLoS One] 2024 Jul 25; Vol. 19 (7), pp. e0307568. Date of Electronic Publication: 2024 Jul 25 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
مواضيع طبية MeSH: | COVID-19*/epidemiology , COVID-19*/diagnosis , COVID-19*/immunology , COVID-19*/blood , SARS-CoV-2*/immunology , SARS-CoV-2*/isolation & purification , Hispanic or Latino*, Humans ; Female ; Male ; Adult ; Cross-Sectional Studies ; Middle Aged ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19 Vaccines/immunology ; Massachusetts/epidemiology ; Saliva/virology ; Saliva/immunology ; Black or African American ; COVID-19 Serological Testing/methods ; Aged |
مستخلص: | COVID-19 disproportionately affected minorities, while research barriers to engage underserved communities persist. Serological studies reveal infection and vaccination histories within these communities, however lack of consensus on downstream evaluation methods impede meta-analyses and dampen the broader public health impact. To reveal the impact of COVID-19 and vaccine uptake among diverse communities and to develop rigorous serological downstream evaluation methods, we engaged racial and ethnic minorities in Massachusetts in a cross-sectional study (April-July 2022), screened blood and saliva for SARS-CoV-2 and human endemic coronavirus (hCoV) antibodies by bead-based multiplex assay and point-of-care (POC) test and developed across-plate normalization and classification boundary methods for optimal qualitative serological assessments. Among 290 participants, 91.4% reported receiving at least one dose of a COVID-19 vaccine, while 41.7% reported past SARS-CoV-2 infections, which was confirmed by POC- and multiplex-based saliva and blood IgG seroprevalences. We found significant differences in antigen-specific IgA and IgG antibody outcomes and indication of cross-reactivity with hCoV OC43. Finally, 26.5% of participants reported lingering COVID-19 symptoms, mostly middle-aged Latinas. Hence, prolonged COVID-19 symptoms were common among our underserved population and require public health attention, despite high COVID-19 vaccine uptake. Saliva served as a less-invasive sample-type for IgG-based serosurveys and hCoV cross-reactivity needed to be evaluated for reliable SARS-CoV-2 serosurvey results. The use of the developed rigorous downstream qualitative serological assessment methods will help standardize serosurvey outcomes and meta-analyses for future serosurveys beyond SARS-CoV-2. Competing Interests: The authors have declared that no competing interests exist. (Copyright: © 2024 Binder et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
التعليقات: | Update of: medRxiv. 2024 May 24:2024.05.23.24307817. doi: 10.1101/2024.05.23.24307817. (PMID: 38826359) |
References: | J Clin Invest. 2021 Jan 4;131(1):. (PMID: 32997649) Clin Infect Dis. 2021 Dec 16;73(12):2366-2368. (PMID: 33693643) JAMA. 2020 May 26;323(20):2052-2059. (PMID: 32320003) Adv Virus Res. 2018;100:163-188. (PMID: 29551135) Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662) Clin Infect Dis. 2021 Feb 16;72(4):703-706. (PMID: 32562416) Clin Infect Dis. 2021 Aug 2;73(3):554-555. (PMID: 32926168) Sci Rep. 2022 Sep 02;12(1):14932. (PMID: 36056118) Clin Vaccine Immunol. 2010 Jan;17(1):185-9. (PMID: 19923569) Clin Chem. 2020 Jul 1;66(7):875-877. (PMID: 32343775) Antibodies (Basel). 2020 Dec 15;9(4):. (PMID: 33333967) J Oral Microbiol. 2013;5:. (PMID: 23487566) JAMA Health Forum. 2021 Mar 1;2(3):e210434. (PMID: 36218456) J Clin Med. 2020 May 15;9(5):. (PMID: 32429101) Clin Transl Immunology. 2021 Mar 14;10(3):e1261. (PMID: 33747511) Ann Intern Med. 2021 Mar;174(3):362-373. (PMID: 33253040) Exp Ther Med. 2022 Jun;23(6):391. (PMID: 35495593) Microbiol Spectr. 2022 Dec 21;10(6):e0271622. (PMID: 36219096) Nat Commun. 2022 Sep 1;13(1):5135. (PMID: 36050304) Lancet Microbe. 2023 Oct;4(10):e837-e850. (PMID: 37516121) J Infect Dis. 2020 Aug 17;222(6):890-893. (PMID: 32599614) N Engl J Med. 2021 Jul 8;385(2):97-100. (PMID: 33789007) J Infect Dis. 2023 Feb 1;227(3):371-380. (PMID: 36314635) Bull Natl Res Cent. 2021;45(1):133. (PMID: 34335014) Elife. 2021 Mar 05;10:. (PMID: 33666169) Trends Endocrinol Metab. 2023 Jun;34(6):321-344. (PMID: 37080828) Res Soc Stratif Mobil. 2020 Oct;69:100553. (PMID: 32921870) Vaccines (Basel). 2023 Mar 06;11(3):. (PMID: 36992183) J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234. (PMID: 36340059) J Immunol. 2020 Dec 15;205(12):3491-3499. (PMID: 33127820) JAMA. 2021 Oct 12;326(14):1400-1409. (PMID: 34473201) Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. (PMID: 33400782) Contemp Clin Trials. 2008 Nov;29(6):847-61. (PMID: 18721901) Sci Immunol. 2020 Oct 8;5(52):. (PMID: 33033173) J Clin Virol. 2012 Feb;53(2):135-9. (PMID: 22188723) |
معلومات مُعتمدة: | KL2 TR001455 United States TR NCATS NIH HHS; U01 CA261276 United States CA NCI NIH HHS |
المشرفين على المادة: | 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) |
تواريخ الأحداث: | Date Created: 20240725 Date Completed: 20240725 Latest Revision: 20240730 |
رمز التحديث: | 20240730 |
مُعرف محوري في PubMed: | PMC11271856 |
DOI: | 10.1371/journal.pone.0307568 |
PMID: | 39052608 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1932-6203 |
---|---|
DOI: | 10.1371/journal.pone.0307568 |